PT  - JOURNAL ARTICLE
AU  - Mares, Jan
AU  - Hartung, Hans-Peter
TI  - Multiple sclerosis and COVID-19
DP  - 2020 Sep 17
TA  - Biomedical papers
PG  - 217--225
VI  - 164
IP  - 3
AID - 10.5507/bp.2020.033
IS  - 12138118
AB  - This paper reviews currently available data on the novel coronavirus and clinical features of COVID-19, followed by a detailed section on possible modifications of immunomodulatory therapy in multiple sclerosis patients with COVID-19, based on what we know so far. There are discussed: (i) The COVID-19 disease (Epidemiological background SARS-CoV-1 coronavirus; Autoimmune response to COVID-19; Asymptomatic course; SARS-CoV-2 test; COVID-19 symptoms), (ii) Treatment of COVID-19 (Experimental plasma treatment; Antiviral therapy; Antimalarial treatment scheme; Biological treatment; Corticosteroid treatment; Symptomatic treatment; Vaccine preparation) and (iii) Multiple sclerosis and SARS-CoV-2 infection (Epidemiological recommendation).